Oxford University and AstraZeneca announced the first interim analysis from the Phase III study of its COVID-19 vaccine candidate, which was found to be 70% effective in preventing COVID-19. This follows similar announcements from Moderna, and Pfizer/BioNTech in the previous two weeks, and the caveats we mentioned at the time remain the same. While all of these results have been highly encouraging, we reiterate that they do not diminish the urgent need for COVID-19 treatments and testing, which ....
23 Nov 2020
Rude Health - finnCap Life Sciences quarterly sector note
Avacta Group PLC (AVCT:LON), 132 | Omega Diagnostics Group PLC (ODX:LON), 57.0 | Synairgen plc (SNG:LON), 162 | Genedrive Plc (GDR:LON), 43.5 | Open Orphan Plc (ORPH:LON), 25.2
-
-
-
Mark Brewer | Arshad Ahad
-
5 pages
-


Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Rude Health - finnCap Life Sciences quarterly sector note
Avacta Group PLC (AVCT:LON), 132 | Omega Diagnostics Group PLC (ODX:LON), 57.0 | Synairgen plc (SNG:LON), 162 | Genedrive Plc (GDR:LON), 43.5 | Open Orphan Plc (ORPH:LON), 25.2
- Published:
23 Nov 2020 -
Author:
Mark Brewer | Arshad Ahad -
Pages:
5 -
Oxford University and AstraZeneca announced the first interim analysis from the Phase III study of its COVID-19 vaccine candidate, which was found to be 70% effective in preventing COVID-19. This follows similar announcements from Moderna, and Pfizer/BioNTech in the previous two weeks, and the caveats we mentioned at the time remain the same. While all of these results have been highly encouraging, we reiterate that they do not diminish the urgent need for COVID-19 treatments and testing, which ....